Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Excretion: Miscellaneous Routes01:10

Drug Excretion: Miscellaneous Routes

Drug excretion involves various organs, including the liver, intestines, skin, and eyes. In the case of drugs or toxins, they can be actively secreted into bile by transporters in the hepatocyte's canalicular membrane. These substances enter the GI tract during digestion and may be reabsorbed into the body from the intestine. This process, known as enterohepatic recycling, can significantly prolong the presence and effects of a substance in the body. To interrupt this cycle, specific substances...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The protective role of phosphodiesterase inhibitors in preventing colorectal cancer and advanced colorectal polyps: a systematic review and meta-analysis.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2023
Same author

Monitoring SARS-CoV-2 decontamination by dry heat and ultraviolet treatment with a swine coronavirus as a surrogate.

Infection prevention in practice·2021
Same author

Correction to: HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study.

Hernia : the journal of hernias and abdominal wall surgery·2020
Same author

Early antibody responses map to non-protective, PCV2 capsid protein epitopes.

Virology·2019
Same author

HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study.

Hernia : the journal of hernias and abdominal wall surgery·2019
Same author

The Noradrenergic System of Aged GDNF Heterozygous Mice.

Cell transplantation·2017

Related Experiment Video

Updated: Jun 1, 2026

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice
09:50

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice

Published on: April 24, 2013

Exposing fetal drug exposure.

L DeVane1, L M Goetzl, S Ramamoorthy

  • 1Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA. devaneL@musc.edu

Clinical Pharmacology and Therapeutics
|May 20, 2011
PubMed
Summary
This summary is machine-generated.

Pregnancy does not protect women from illness or reduce medication needs. Maintaining maternal health while minimizing fetal drug exposure is crucial due to potential unknown risks to the fetus.

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 1, 2026

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice
09:50

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice

Published on: April 24, 2013

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

Area of Science:

  • Reproductive Medicine
  • Pharmacology
  • Maternal-Fetal Health

Background:

  • Pregnancy does not confer immunity to illnesses.
  • Existing pharmacotherapy dosages generally remain unchanged during pregnancy.
  • Maternal health maintenance is a key consideration during drug use in pregnancy.

Purpose of the Study:

  • To highlight the importance of minimizing fetal drug exposure.
  • To address the risks associated with medication use during pregnancy.
  • To emphasize the need for careful management of pharmacotherapy in pregnant individuals.

Main Methods:

  • Review of existing literature on drug use in pregnancy.
  • Analysis of pharmacokinetic and pharmacodynamic changes during gestation.
  • Evaluation of risk-benefit assessments for medications in pregnant populations.

Main Results:

  • Pregnancy does not alter susceptibility to illness.
  • Drug dosage requirements typically do not decrease during pregnancy.
  • Fetal exposure to any medication carries potential, often unknown, risks.

Conclusions:

  • Minimizing fetal drug exposure is a primary goal in managing pharmacotherapy during pregnancy.
  • Prudent medication management is essential to balance maternal health and fetal safety.
  • Further research is needed to fully elucidate medication risks during pregnancy.